ArticleCureus2025
Henoch-Schönlein Purpura Without Proven Immunoglobin A Deposition: A Diagnostic Distinction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Henoch-Schönlein purpura (HSP), or immunoglobulin A (IgA) vasculitis (IgAV), is a small vessel vasculitis that is most commonly seen in children; it is classically characterized by IgA deposition within the renal mesangium, resulting in a wide range of symptoms: palpable purpura, arthralgia, gastrointestinal symptoms, renal involvement, and, in severe cases, pulmonary complications or intussusception. Diagnosis relies upon clinical symptoms, histopathology, and direct immunofluorescence (DIF) testing to differentiate HSP from other vasculitides. DIF typically reveals IgA deposits; however, negative DIF findings do not rule out the diagnosis, which indicates the need for an adaptable diagnostic approach. Groups such as the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) categorize positive IgA as supportive data for an HSP diagnosis but not as a necessity. We present the case of a 14-year-old male with progressive ascending palpable purpura, significant abdominal pain, and lower extremity edema. Histopathological analysis of the skin biopsy confirmed leukocytoclastic vasculitis (LCV); however, his DIF was negative for IgG, IgA, IgM, C3, and fibrinogen deposits. At the time of biopsy, his workup was significant for an isolated elevated alanine aminotransferase (ALT), but urinalysis and renal function testing were unremarkable. Despite a negative DIF, the patient's findings were clinically consistent with HSP, and hence, a diagnosis was made. He was started on a prednisone taper and supportive care for management. After initial improvement, he experienced a flare warranting an additional course of steroids, which improved his symptoms. This report underscores the diagnostic challenges associated with HSP, particularly with negative DIF. While DIF serves as a useful tool in the classification of certain vasculitides, its sensitivity is influenced by the biopsy site, lesion age, and degradation of immune complexes. Providers should maintain a high index of suspicion and carefully consider histopathologic findings and laboratory data when diagnosing HSP. Further research is needed to refine the diagnostic applicability of DIF and its association with disease severity and systemic involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.